SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Clearmind Medicine Inc.
Date: Feb. 25, 2026 · CIK: 0001892500 · Accession: 0000000000-26-001956

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293521

Date
February 25, 2026
Author
Adi Zuloff-Shani
Form
UPLOAD
Company
Clearmind Medicine Inc.

Letter

February 25, 2026 Adi Zuloff-Shani Chief Executive Officer Clearmind Medicine Inc. 101 – 1220 West 6th Avenue Vancouver, British Columbia V6H1A5 Re:Clearmind Medicine Inc. Registration Statement on Form F-3 Filed February 17, 2026 File No. 333-293521 Dear Adi Zuloff-Shani: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:David Huberman

Show Raw Text
February 25, 2026
Adi Zuloff-Shani
Chief Executive Officer
Clearmind Medicine Inc.
101 – 1220 West 6th Avenue
Vancouver, British Columbia V6H1A5
Re:Clearmind Medicine Inc.
Registration Statement on Form F-3
Filed February 17, 2026
File No. 333-293521
Dear Adi Zuloff-Shani:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:David Huberman